AstraZeneca Able to Scrap Plans for US Approval of COVID Shot
(Reuters) – An AstraZeneca Plc executive said the British drugmaker would consider not submitting its COVID-19 vaccine for approval in the United States if the regulatory process takes too long, the Financial Times reported on Thursday. The company’s research and development head, Mene Pangalos, said AstraZeneca would instead focus on selling the vaccine in other…
